Strategic partnerships LCA offers live cell assay development, imaging and VSOM software and is actively seeking qualified investors and contract research customers, presenting an opportunity to target biotech firms needing custom imaging analytics and automated decision-making systems.

Niche expertise With patented VSOM based automation and subcellular time-lapse analysis, LCA can provide specialized imaging workflow integrations for labs focused on live cell kinetics and cancer stem cell tracking in PDX tissue.

Ex vivo expansion The development of ex vivo VSOM assays for long-term tracking of living cancer stem cells in PDX slices opens up potential sales in translational research, precision oncology and pharma partnership programs requiring advanced imaging analytics.

Revenue growth potential Current revenue range indicates a growing, cash-flow-positive small business opportunity; potential upsell paths include expanded contract research, software licensing for customized VSOM packages, and ongoing maintenance for imaging workflows.

Tech stack alignment Despite a lean tech stack, LCA’s software-centric approach and messaging around automated decision-making align with biotech customers investing in digital pathology, high-content imaging, and image analysis platforms for scalable research.